Mayo Clinic maps meningioma behavior
Analysis based on 6 articles · First reported Jun 09, 2026 · Last updated Jun 10, 2026
This medical breakthrough could significantly impact the biotechnology and healthcare sectors by leading to new diagnostic tools and personalized treatments for meningioma. Companies involved in cancer research, diagnostics, and therapeutics may see increased investment and development opportunities.
Researchers at Mayo Clinic and Princess Margaret Cancer Centre have created one of the most detailed maps of meningioma, the most common brain tumor in adults. The study, published in Nature Genetics, reveals how the tumor's surrounding environment influences its behavior and patient outcomes. Led by neurosurgeon Gelareh Zadeh>>> of Mayo Clinic, the research utilized single-cell sequencing and spatial transcriptomics to analyze over 500,000 individual cells, creating a high-resolution 'atlas' of genetic footprints. This breakthrough offers clues to why some meningiomas are aggressive while others are benign, potentially leading to more precise risk prediction, personalized treatment decisions, and noninvasive monitoring through blood-based biomarkers. The findings also highlight potential therapeutic targets by identifying communication pathways between immune and tumor cells.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard